Literature DB >> 21464730

Diagnostic immunohistochemistry in uterine sarcomas: a study of 397 cases.

Vera M Abeler1, Maja Nenodovic.   

Abstract

The purpose of this study was to evaluate the use of a broad panel of antibodies used as diagnostic markers for abdominal mesenchymal tumors in uterine sarcomas. The expression of vimentin, AE1/AE3, smooth muscle actin (SMA), desmin , h-caldesmon, actin, Myf4, CD10, CD31, CD68, CD117, factor VIII, HMB-45, and S-100 protein was studied in 397 uterine sarcomas. SMA was positive in 90% of the ordinary leiomyosarcomas and when combined with desmin or h-caldesmon, a positivity of 96% and 92%, respectively, was achieved. Actin and Myf4 were positive in 4 of 5 rhabdomyosarcomas. Endometrial stromal sarcomas reacted positive with CD10 in 62 of 84 tumors and negative with h-caldesmon in 75 of 84 tumors. CD10 was the most frequent positive marker in adenosarcoma. Most tumor markers stained negative in undifferentiated uterine sarcoma, but 12 of 21 tumors reacted positive for SMA. A few focally HMB-45-positive cells were found within all tumor groups, except in rhabdomyosarcomas and giant cell tumors. Endothelial markers, S-100 protein, and CD117 do not seem to be of any diagnostic value in uterine sarcomas. In conclusion, when immunohistochemistry is used diagnostically in uterine sarcomas, a broad panel of markers provides better information than reliance on a single antibody.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21464730     DOI: 10.1097/PGP.0b013e318200caff

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  15 in total

1.  Novel High-grade Endometrial Stromal Sarcoma: A Morphologic Mimicker of Myxoid Leiomyosarcoma.

Authors:  Lien N Hoang; Amandeep Aneja; Niamh Conlon; Deborah F Delair; Sumit Middha; Ryma Benayed; Martee L Hensley; Kay J Park; Travis J Hollmann; Meera R Hameed; Cristina R Antonescu; Robert A Soslow; Sarah Chiang
Journal:  Am J Surg Pathol       Date:  2017-01       Impact factor: 6.394

2.  Gene expression signatures of primary and metastatic uterine leiomyosarcoma.

Authors:  Ben Davidson; Vera Maria Abeler; Mette Førsund; Arild Holth; Yanqin Yang; Yusuke Kobayashi; Lily Chen; Gunnar B Kristensen; Ie-Ming Shih; Tian-Li Wang
Journal:  Hum Pathol       Date:  2013-11-13       Impact factor: 3.466

3.  Transgelin, a Novel Marker of Smooth Muscle Differentiation, Effectively Distinguishes Endometrial Stromal Tumors from Uterine Smooth Muscle Tumors.

Authors:  Ossama Tawfik; Deepthi Rao; Warren B Nothnick; Amanda Graham; Brian Mau; Fang Fan
Journal:  Int J Gynecol Obstet Reprod Med Res       Date:  2014-09

4.  High-grade endometrial stromal sarcoma versus undifferentiated uterine sarcoma: a Turkish uterine sarcoma group study-001.

Authors:  Ali Ayhan; Mehmet Tunc; Nurettin Boran; Ghanim Khatib; Mehmet Gokcu; Tayup Simsek; Ozlem Isiksacan Ozen; Tayfun Toptas; Ibrahim Yalcin; Mehmet Mutlu Meydanli
Journal:  Arch Gynecol Obstet       Date:  2021-01-03       Impact factor: 2.344

Review 5.  Uterine Adenosarcoma: a Review.

Authors:  Michael J Nathenson; Vinod Ravi; Nicole Fleming; Wei-Lien Wang; Anthony Conley
Journal:  Curr Oncol Rep       Date:  2016-11       Impact factor: 5.075

6.  Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma.

Authors:  Ben Davidson; Ellen Hellesylt; Arild Holth; Håvard Emil Danielsen; Tone Skeie-Jensen; Betina Katz
Journal:  Virchows Arch       Date:  2017-06-22       Impact factor: 4.064

7.  Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma.

Authors:  Ben Davidson; Vera Maria Abeler; Ellen Hellesylt; Arild Holth; Ie-Ming Shih; Tone Skeie-Jensen; Li Chen; Yanqin Yang; Tian-Li Wang
Journal:  Gynecol Oncol       Date:  2012-11-21       Impact factor: 5.482

8.  Synchronous uterine carcinosarcoma and contralateral breast cancer after tamoxifen therapy: a case report.

Authors:  Ling Shen; Liangli Hong; Guohong Zhang; Ruiqin Mai
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

9.  TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition.

Authors:  Sarah Chiang; Varshini Vasudevaraja; Jonathan Serrano; Colin J R Stewart; Esther Oliva; Amir Momeni-Boroujeni; Achim A Jungbluth; Arnaud Da Cruz Paula; Edaise M da Silva; Britta Weigelt; Kay J Park; Robert A Soslow; Rajmohan Murali; Lora H Ellenson; Ryma Benayed; Marc Ladanyi; Nadeem R Abu-Rustum; Mark A Dickson; Seth Cohen; Carol Aghajanian; Martee L Hensley; Cheng-Han Lee; Matija Snuderl; Jason A Konner
Journal:  Mod Pathol       Date:  2021-09-24       Impact factor: 8.209

10.  Successful pregnancy following conservative management of low-grade endometrial stromal sarcoma: A case report.

Authors:  Ruiying Dong; Yingxin Pang; Hongluan Mao; Ning Yang; Peishu Liu
Journal:  Oncol Lett       Date:  2014-02-07       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.